Innovative Deal Between NHS England, NICE and Manufacturer Alexion Allows Patient Access to Rare Disease Drug

Hypophosphatasia (HPP) is a rare inherited bone condition which is often fatal in baby and debilitating in older children and adults. The disease can lead to bone deformities and affect 1 per 6,370 of the population. The drug asfotase alfa was previously only recommended for use in babies by NICE in draft guidance, as evidence showed it could be life-saving.

A new ‘managed access agreement’ between NHS England and manufacturer Alexion, alongside new draft NICE guidance, will broaden access of asfotase alfa to infants, children and adult patients with paediatric-onset HPP, who experience the most disabling symptoms and are expected to benefit most from therapy. The deal is considered novel because it is a value-based risk sharing agreement to provide wider cost-effective access for patients, informed by their first-hand experience of the ongoing impact that treatment is having on their health and quality of life.

To read more about this, please click here.

Tagged with

Published on 5. July 2017 in News UK